ATE448234T1 - Olanzapin-analoga und verfahren zu ihrer verwendung - Google Patents

Olanzapin-analoga und verfahren zu ihrer verwendung

Info

Publication number
ATE448234T1
ATE448234T1 AT06801404T AT06801404T ATE448234T1 AT E448234 T1 ATE448234 T1 AT E448234T1 AT 06801404 T AT06801404 T AT 06801404T AT 06801404 T AT06801404 T AT 06801404T AT E448234 T1 ATE448234 T1 AT E448234T1
Authority
AT
Austria
Prior art keywords
methods
olnzapine
analogues
relates
novel compounds
Prior art date
Application number
AT06801404T
Other languages
English (en)
Inventor
James White
Kazumi Shiosaki
David Hangauer
Michael Solomon
Dale Edgar
Original Assignee
Hypnion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hypnion Inc filed Critical Hypnion Inc
Application granted granted Critical
Publication of ATE448234T1 publication Critical patent/ATE448234T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT06801404T 2005-08-11 2006-08-11 Olanzapin-analoga und verfahren zu ihrer verwendung ATE448234T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70736805P 2005-08-11 2005-08-11
US11/502,789 US7807828B2 (en) 2005-08-11 2006-08-10 Olanzapine analogs and methods of use thereof
PCT/US2006/031602 WO2007022068A1 (en) 2005-08-11 2006-08-11 Olanzapine analogs and methods of use thereof

Publications (1)

Publication Number Publication Date
ATE448234T1 true ATE448234T1 (de) 2009-11-15

Family

ID=37460090

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06801404T ATE448234T1 (de) 2005-08-11 2006-08-11 Olanzapin-analoga und verfahren zu ihrer verwendung

Country Status (8)

Country Link
US (1) US7807828B2 (de)
EP (1) EP1915379B1 (de)
JP (1) JP2009504676A (de)
AT (1) ATE448234T1 (de)
CA (1) CA2617107C (de)
DE (1) DE602006010400D1 (de)
ES (1) ES2333983T3 (de)
WO (1) WO2007022068A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7910577B2 (en) * 2004-11-16 2011-03-22 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
WO2007092333A1 (en) * 2006-02-03 2007-08-16 Hypnion, Inc. Use of olopatadine for treating sleep disorders
CN101636182B (zh) 2006-10-25 2013-01-16 雷蒙特亚特特拉维夫大学有限公司 具有谷氨酸nmda活性的新型精神病治疗剂
US8258306B2 (en) 2007-12-12 2012-09-04 Amgen Inc. Glycine transporter-1 inhibitors
AR084867A1 (es) * 2011-02-07 2013-07-10 Lilly Co Eli Compuestos de acido [(5h-pirrolo[2,1-c][1,4]benzodiazepin-11-il)piperazin-1-il]-2,2-dimetilpropanoico sustituido como antagonistas de 5-ht/agonistas inversos de actividad dual
PL395468A1 (pl) 2011-06-29 2013-01-07 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Zwiazki amidoalkilopiperazynylowe do leczenia chorób osrodkowego ukladu nerwowego
KR101582429B1 (ko) 2011-07-08 2016-01-04 일라이 릴리 앤드 캄파니 이중 활성 H1 역 효능제/5-HT2A 길항제로서의 (티에노[2,3-b][1,5]벤족사제핀-4-일)피페라진-1-일 화합물
PL2751115T3 (pl) * 2011-08-30 2018-02-28 Eli Lilly And Company Związki (tieno[2,3-b][1,5]benzoksazepin-4-ylo)piperazyn-1-ylowe o podwójnym działaniu jako odwrotni agoniści receptora H1 / antagoniści receptora 5-HT2A
HRP20171731T1 (hr) * 2013-01-14 2017-12-29 Eli Lilly And Company (TIENO[2,3-b][1,5]BENZOKSAZEPIN-4-IL)PIPERAZIN-1-ILNI SPOJEVI S DVOJNOM AKTIVNOŠĆU INVERZNIH AGONISTA H1 I ANTAGONISTA 5-HT2A
TW201625644A (zh) 2014-04-29 2016-07-16 美國禮來大藥廠 作為選擇性５－ＨＴＡ反向促效劑之（噻吩并［２，３－ｂ］［１，５］苯并氧氮呯－４－基）哌嗪－１－基化合物
AU2019205329B2 (en) * 2018-01-05 2023-04-20 Impel Pharmaceuticals Inc. Intranasal delivery of olanzapine by precision olfactory device
BR112022007503A2 (pt) * 2019-10-21 2022-07-12 Alairion Inc Derivados de ácido 3-(4-(11h-dibenzo[b,e][1,4]azepin-6-il)piperazin-1-il)- e 3-(4-(11h-dibenzo[b,f][1,4]oxazepin/tiazepin/diazepin-11-il)piperazin-1-il)-propanoico como moduladores de receptor de h1 e 5-ht2a para o tratamento de distúrbios do sono
CN114685527B (zh) * 2020-12-25 2024-03-05 长沙博源医疗科技有限公司 一种奥氮平衍生物、免疫原、抗奥氮平特异性抗体及其制备方法与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04211071A (ja) * 1990-03-05 1992-08-03 Hokuriku Seiyaku Co Ltd 多環式化合物
US5602124A (en) 1994-12-12 1997-02-11 Allelix Biopharmaceuticals, Inc. 5-HT2 receptor ligands
US5744470A (en) * 1996-03-11 1998-04-28 Eli Lilly And Company Method for treating insomnia
KR20010021989A (ko) * 1997-09-02 2001-03-15 가마후라 아키오 축합 티오펜 화합물 및 이의 의약 용도
US7355042B2 (en) * 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
AU2002347906A2 (en) * 2001-10-16 2003-04-28 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
JP2007505106A (ja) 2003-09-09 2007-03-08 イーライ リリー アンド カンパニー アゼピン、オキサゼピン、およびチアゼピンの置換ピペラジン

Also Published As

Publication number Publication date
DE602006010400D1 (de) 2009-12-24
EP1915379A1 (de) 2008-04-30
CA2617107A1 (en) 2007-02-22
ES2333983T3 (es) 2010-03-03
US20070043021A1 (en) 2007-02-22
US7807828B2 (en) 2010-10-05
WO2007022068A1 (en) 2007-02-22
JP2009504676A (ja) 2009-02-05
EP1915379B1 (de) 2009-11-11
CA2617107C (en) 2014-07-08

Similar Documents

Publication Publication Date Title
ATE513833T1 (de) Thienopyridinverbindungen und verfahren zu ihrer verwendung
NO20071604L (no) Loxapinanaloger og fremgangsmater for anvendelse derav.
CY1112653T1 (el) Κρυσταλλικες τροποποιησεις της πυρακλοστροβινης
UY3493Q (es) Esponja
CY1110026T1 (el) Ενωσεις πιπεραζινης βενζισοξαζολης και μεθοδοι χρησης εξ αυτων
NO20071127L (no) Triazoloftalaziner
ATE532518T1 (de) Dipeptidyl-peptidase-hemmer zur behandlung von diabetes
EP1971883A4 (de) Statistisches deterministisches verfahren zur vorhersage von naturkatastrophen
ATE473744T1 (de) Modifizierte pyrimidin-glucocorticoid-rezeptor- modulatoren
ATE477249T1 (de) Heteroarylbenzamidderivate zur verwendung als glk-aktivatoren bei der behandlung von diabetes
TW200640924A (en) VEGF-R2 inhibitors and methods
ATE543910T1 (de) Verfahren und materialien zur herstellung von simvastatin und verwandten verbindungen
MX2007008137A (es) Triazoloftalazinas como inhibidores de pde2.
WO2006049734A3 (en) Quetiapine analogs and methods of use thereof
DE602006004463D1 (de) Kristallform von asenapinmaleat
ATE448234T1 (de) Olanzapin-analoga und verfahren zu ihrer verwendung
ATE493986T1 (de) Diarylharnstoffe zur behandlung von pulmonaler hypertonie
ATE540755T1 (de) Verwendung von katalysatorzusammensetzungen und verfahren zur oxychlorierung
ATE495243T1 (de) Verfahren zur herstellung von hochempfindlichen endonukleasen, neuartige zubereitungen von nukleasen und ihre verwendung
DE602006017367D1 (de) Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut
ATE439831T1 (de) Stabile kristalline form von bifeprunoxmesylat, dosierungsformen davon und verfahren zu deren verwendung
DE502007003652D1 (de) Verwendung von nitratsalzen zur unterdrückung störender gerüche
DE502007006880D1 (de) Verwendung von gallium (iii) komplexen zur behandlung von melanomen
DE602006009513D1 (de) Verwendung von phenylsemicarbazonen für die saatgutbeizung
DE602006007323D1 (de) VERWENDUNG VON BAFF ZUR BEHANDLUNG Th2-INDUZIERTER LEIDEN

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties